LGND
Ligand Pharmaceuticals Inc
$
154.235
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
155.885
Open
150.500
VWAP
153.08
Vol
288.70K
Mkt Cap
2.88B
Low
149.950
Amount
44.20M
EV/EBITDA(TTM)
--
Total Shares
17.96M
EV
2.64B
EV/OCF(TTM)
47.62
P/S(TTM)
14.99
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
51.08M
+12.68%
--
--
59.77M
+39.61%
--
--
56.17M
+8.41%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Ligand Pharmaceuticals Incorporated (LGND) for FY2025, with the revenue forecasts being adjusted by 0.6% over the past three months. During the same period, the stock price has changed by 44.98%.
Revenue Estimates for FY2025
Revise Upward
+0.6%
In Past 3 Month
Stock Price
Go Up
+44.98%
In Past 3 Month
7 Analyst Rating
-3.28% Downside
Wall Street analysts forecast LGND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGND is 149.17 USD with a low forecast of 135.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
-3.28% Downside
Current: 154.235
Low
135.00
Averages
149.17
High
162.00
-3.28% Downside
Current: 154.235
Low
135.00
Averages
149.17
High
162.00
RBC Capital
NULL
to
Outperform
maintain
$155 -> $185
2025-08-08
New
Reason
RBC Capital
Price Target
$155 -> $185
2025-08-08
New
maintain
NULL
to
Outperform
Reason
RBC Capital raised the firm's price target on Ligand to $185 from $155 and keeps an Outperform rating on the shares. The company's Q2 revenue beat was driven by better-than-expected Royalty and Captisol performance, the analyst tells investors in a research note.
Benchmark
Buy
maintain
$135 -> $160
2025-08-08
New
Reason
Benchmark
Price Target
$135 -> $160
2025-08-08
New
maintain
Buy
Reason
Benchmark raised the firm's price target on Ligand to $160 from $135 and keeps a Buy rating on the shares after the company reported better-than-expected Q2 results and raised FY25 guidance. For FY25, the firm is now forecasting that Ligand will grow revenue 29% year-over-year to $215M with adjusted EPS of $6.85, up from $5.72 last year.
Oppenheimer
Leland Gershell
Outperform
maintain
$145 -> $162
2025-07-30
Reason
Oppenheimer
Leland Gershell
Price Target
$145 -> $162
2025-07-30
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Ligand to $162 from $145 and keeps an Outperform rating on the shares after hosting virtual non-deal roadshows early this week with the company's management. Investors were broadly bulled-up on recent developments and management's conservative forecasts for its current royalty portfolio. CEO Todd Davis highlighted a few key wins that demonstrate Ligand's aptitude, such as its initial investment in Ohtuvayre royalties, its recent incubation and spin of Pelthos and Palvella, and Qarziba's $20M-plus annualized royalty for $100M.
Oppenheimer
Oppenheimer
Outperform
maintain
$142 -> $145
2025-05-09
Reason
Oppenheimer
Oppenheimer
Price Target
$142 -> $145
2025-05-09
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Ligand to $145 from $142 and keeps an Outperform rating on the shares following quarterly results. Ligand remains in early stages of executing their royalty strategy, and the firm expects continued execution across the portfolio, further supported by deal-making throughout 2025.
Stifel
Annabel Samimy
Strong Buy
Initiates
$143
2025-04-10
Reason
Stifel
Annabel Samimy
Price Target
$143
2025-04-10
Initiates
Strong Buy
Reason
Stifel initiated coverage of Ligand with a Buy rating and $143 price target. Ligand, which provides "an important source of differentiated capital" through royalty-financing deals to mid-late stage biopharma companies looking for non-dilutive funding, holds "one of the most diversified portfolios" of royalty revenues across therapeutic areas for de-risked exposure to biopharma development, the analyst tells investors. The firm sees Ligand having growth prospects of greater than 20% through 2029 and its strategy "largely shielding itself from the classic volatility of the biopharma industry."
Benchmark
Robert Wasserman
Strong Buy
Reiterates
$135
2024-12-23
Reason
Benchmark
Robert Wasserman
Price Target
$135
2024-12-23
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ligand Pharmaceuticals Inc (LGND.O) is 46.69, compared to its 5-year average forward P/E of -9.34. For a more detailed relative valuation and DCF analysis to assess Ligand Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.34
Current PE
46.69
Overvalued PE
143.81
Undervalued PE
-162.49
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
17.64
Current EV/EBITDA
20.35
Overvalued EV/EBITDA
23.98
Undervalued EV/EBITDA
11.29
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
10.18
Current PS
13.06
Overvalued PS
12.24
Undervalued PS
8.11
Financials
Annual
Quarterly
FY2025Q2
YoY :
+14.68%
47.63M
Total Revenue
FY2025Q2
YoY :
-3.02%
7.17M
Operating Profit
FY2025Q2
YoY :
-109.34%
4.85M
Net Income after Tax
FY2025Q2
YoY :
-108.33%
0.24
EPS - Diluted
FY2025Q2
YoY :
+20.76%
15.59M
Free Cash Flow
FY2025Q2
YoY :
+4.70%
76.56
Gross Profit Margin - %
FY2025Q2
YoY :
-365.12%
28.58
FCF Margin - %
FY2025Q2
YoY :
-108.14%
10.18
Net Margin - %
FY2025Q2
YoY :
-100.00%
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
292.6K
USD
4
3-6
Months
679.1K
USD
2
6-9
Months
244.8K
USD
1
0-12
Months
2.3M
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
2
1.2M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
189.8K
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
109.7K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
292.6K
USD
4
3-6
Months
679.1K
USD
2
6-9
Months
244.8K
USD
1
0-12
Months
2.3M
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
2
1.2M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LGND News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
07:21:38
Ligand announces proposed offering of $400M of convertible senior notes
2025-08-07 (ET)
2025-08-07
07:25:07
Ligand raises FY25 adjusted EPS view to $6.70-$7.00 from $6.00-$6.25
2025-08-07
07:24:16
Ligand reports Q2 adjusted EPS $1.60, consensus $1.42
Sign Up For More Events
Sign Up For More Events
News
8.5
06:00 AMNASDAQ.COMPinnedLigand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes
8.5
03:46 AMNewsfilterPinnedLigand Announces Pricing of $400 Million Convertible Senior Notes Offering
8.5
08-11NASDAQ.COMPinnedLigand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes
Sign Up For More News
People Also Watch
SEI
Solaris Energy Infrastructure Inc
30.740
USD
+1.25%
ZGN
Ermenegildo Zegna NV
7.850
USD
+1.82%
GBX
Greenbrier Companies Inc
46.080
USD
+2.26%
VSEC
VSE Corp
153.640
USD
0.00%
VERA
Vera Therapeutics Inc
20.389
USD
+1.08%
WOR
Worthington Enterprises Inc
63.250
USD
+0.89%
CNMD
Conmed Corp
52.480
USD
0.00%
SUPN
Supernus Pharmaceuticals Inc
41.120
USD
+1.36%
MTRN
Materion Corp
107.170
USD
+1.10%
RAMP
Liveramp Holdings Inc
25.140
USD
-2.41%
FAQ
What is Ligand Pharmaceuticals Inc (LGND) stock price today?
The current price of LGND is 154.235 USD — it has increased 4.91 % in the last trading day.
What is Ligand Pharmaceuticals Inc (LGND)'s business?
What is the price predicton of LGND Stock?
What is Ligand Pharmaceuticals Inc (LGND)'s revenue for the last quarter?
What is Ligand Pharmaceuticals Inc (LGND)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ligand Pharmaceuticals Inc (LGND)'s fundamentals?
How many employees does Ligand Pharmaceuticals Inc (LGND). have?